Purpose: To review the demographics, clinical features, and response of orbital squamous cell carcinoma treated with cemiplimab.
Methods: This is a retrospective multi-institutional series. Patient characteristics, drug dosing, duration, and response to treatment were evaluated.
Results: The study cohort consisted of 11 patients from 5 institutions. All patients received a regimen of 350 mg q 3 weeks and an average of 11.2 cycles (SD 5.8). No patient experienced significant side effects requiring treatment or cessation of cemiplimab. Complete response was achieved in 9 patients (82%) treated with cemiplimab.
Conclusions: Immune checkpoint inhibitors, such as cemiplimab provide a globe-sparing option for the treatment of orbital squamous cell carcinoma. It is important to consider these agents especially when orbital exenteration is the alternative.
Copyright © 2022 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.